Get the Daily Brief
Latest Biotech News
UCSD engineers yeast: cross‑organelle tweaks boost plant‑compound yields
A UC San Diego team reported methods to improve yeast performance as biofactories for complex plant compounds by optimizing cytochrome P450 function and coordinating metabolic activity across...
VCs spin Teijin program into Elevara — finance report
Investors Weatherden and venture capital partners spun Teijin’s internal program into a new company, Elevara, in a financing move covered by BioCentury. The transaction includes seed financing and...
Biogen licenses Vanqua C5aR1 program: $70M upfront, nearly $1B in milestones
Biogen struck an exclusive global licensing deal for Vanqua Bio’s preclinical C5aR1 inhibitor, paying $70 million up front with up to $990 million in development, regulatory and commercial...
Lilly to acquire Adverum: upfront below last close, gene‑therapy assets included
Eli Lilly agreed to acquire Adverum in a deal that moves gene‑therapy assets and programs into Lilly’s pipeline amid a tough market for standalone gene‑therapy developers. The transaction price...
FDA greenlights new menopause options: nonhormonal therapies expand clinical choices
Two recent U.S. regulatory actions broaden nonhormonal treatment options for menopausal vasomotor symptoms. The FDA approved elinzanetant, a nonhormonal agent shown in multinational trials to...
Inhibrx posts registrational win: ozekibart PFS gains spark BLA plans
Inhibrx reported that ozekibart (INBRX‑109) met the primary endpoint in a registrational phase II trial for advanced or metastatic unresectable chondrosarcoma, delivering statistically significant...
Halda unveils first RIPTAC clinical data: prostate study shows early activity
Halda Therapeutics disclosed initial clinical data from an ongoing study of its RIPTAC small‑molecule platform in prostate cancer, presenting the first human evidence of target engagement and...
Gepotidacin advances as oral UTI drug; gonorrhea review ongoing
Gepotidacin, an oral type II topoisomerase inhibitor marketed as Blujepa for uncomplicated urinary tract infections following its March 2025 approval, is under further regulatory review for use...
Nanopore cfDNA pinpoints tissue origin and pathogens in critical‑care plasma
Researchers adapted nanopore sequencing to analyze plasma cell‑free DNA from critically ill patients, demonstrating simultaneous tissue‑of‑origin signals and pathogen detection in a single stream...
C2S‑Scale LLM repurposes language models for single‑cell biology: pretrained on 50M profiles
A multi‑institution team released Cell2Sentence‑Scale (C2S‑Scale), a family of large language models trained on over 50 million human and mouse transcriptomes and associated annotations to...
Tetraneuron advances upstream gene‑therapy approach for Alzheimer’s: E2F4 AAV program
Tetraneuron described preclinical progress for TET‑101, an AAV‑based gene therapy targeting transcription factor E2F4 to prevent neuronal cell‑cycle re‑entry, proposing an 'upstream' approach to...
CAR‑T and CAR‑NK revive AML hopes: reviews highlight progress and challenges
A recent review mapped advances in CAR‑T and CAR‑NK cell therapies for acute myeloid leukemia, emphasizing engineered cell approaches that target AML antigens while mitigating myeloablation and...
Biogen pays $70M for Vanqua drug – Secures C5aR1 rights
Biogen announced an exclusive global license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front with up to $990 million in potential milestones. Jane Grogan, Biogen’s head...
Lilly widens gene-therapy bet – Acquires Adverum
Eli Lilly moved to expand its gene‑therapy footprint by acquiring Adverum in a deal that transfers Adverum’s ocular gene‑therapy programs into Lilly’s portfolio. The transaction marks a notable...
FDA clears GSK’s Blenrep: Third-line multiple myeloma use
The U.S. Food and Drug Administration restored GSK’s antibody‑drug conjugate Blenrep to the U.S. market with a narrowed approval for third‑line treatment of multiple myeloma. The decision follows...
Inhibrx posts phase II win: Ozekibart extends PFS in chondrosarcoma
Inhibrx reported positive registrational phase II results for ozekibart (INBRX‑109) in advanced or metastatic, unresectable chondrosarcoma, showing a statistically significant improvement in...
Nanopore sequencing detects pathogens and tissue signals in plasma cfDNA
Researchers demonstrated that nanopore sequencing of plasma cell‑free DNA (cfDNA) from critically ill patients can concurrently detect pathogen sequences and tissue‑of‑origin signals from the same...
FDA greenlights elinzanetant: Nonhormonal hot‑flash therapy approved
The FDA approved elinzanetant, a nonhormonal therapy for menopausal hot flashes and night sweats, following multinational clinical trials showing symptomatic benefit. Regulators granted the new...
STING–IL6/STAT3 blockade stops breast cancer bone metastasis
Preclinical researchers reported that interrupting the STING–IL6/STAT3 signaling axis suppressed breast‑cancer bone colonization in experimental models by preventing formation of an osteoclastic...
UCSD tweaks P450s: Yeast become more efficient biofactories for plant compounds
A University of California San Diego team reported engineering strategies that optimize cytochrome P450 activity in yeast, improving production efficiency for valuable plant‑derived compounds. The...